Stem Cells for Drug Developers
|Event Date/Time: Apr 26, 2011||End Date/Time: Apr 28, 2011|
|Registration Date: Apr 26, 2011|
|Early Registration Date: Feb 18, 2011|
Recent breakthroughs in the area of induced pluripotent stem cells offer many exciting prospects, including new opportunities from providing a more readily available source of stem cells to individualised safety and efficacy screening.
However the full potential of stem cells in drug development has not been reached yet. The field is held back by a number of challenges including stem cell differentiation, fully copying the desired phenotype or even producing sufficient numbers for drug development.
The Stem Cells for Drug Developers Summit will address these issues and deliver cutting edge science and case studies. To ensure the agenda is directly relevant to the needs of drug developers it has been inspired by many leading organisations in field, including Novartis, AstraZeneca and Pfizer.
What's on the agenda for Stems Cells for Drug Developers?
Controlling stem cell differentiation into desired lineages
Recapitulation of disease phenotypes in derived cells
Stem cells as a tool for disease research
High throughput screens using stem cells
The potential of induced pluripotent stem cells
Why should you attend Stem Cells for Drug Developers?
Understand new developments in stem cell differentiation and proliferation
Evaluate the use of stem cell derived models for toxicology assessment
Examine whether iPS cell may be valid substitutions for ESCs
Encourage practical discussion of topics in panel discussions
Hear cutting edge case studies
Forecast the applicability of iPS cells in individualized & efficacy screening